How has been the historical performance of Concord Drugs?

Answer:The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.

Breakdown:
Concord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, compared to 44.93 Cr in the previous year, while it was higher at 52.09 Cr and 59.06 Cr in the earlier years. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, which was slightly up from 40.88 Cr in March 2024 but down from 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, showing a modest increase from 4.05 Cr in March 2024, yet lower than the 4.59 Cr and 5.69 Cr recorded in the prior two years. Profit before tax was 0.69 Cr in March 2025, up from 0.63 Cr in March 2024 but significantly down from 1.25 Cr in March 2023 and 2.25 Cr in March 2022. Consequently, profit after tax decreased to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, and it was notably lower than the 0.99 Cr and 1.59 Cr in the previous two years. The earnings per share (EPS) also reflected this decline, dropping to 0.34 in March 2025 from 0.47 in March 2024, and significantly lower than 1.06 and 1.82 in the earlier years. Overall, the financial metrics indicate a downward trajectory in both revenue and profitability for Concord Drugs over the observed period.